Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Having set the stage, Boston plans its performance
Which groups might Boston Scientific bolt on next?
Congenica aims to turn data into information
Sequencing data is all well and good, but what does it mean?
Bayer’s second-to-last medtech stream dries up
Bayer's only remaining medical technology franchise is its radiology business.
Despite the FDA’s best efforts, device approvals crash
Regulatory intervention having limited impact on fostering innovation.
Floating device companies stay at home
Nine IPOs have got away so far this year, and one of them is very big indeed.
